We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Apatinib as a Third-Line Treatment for HER2-Positive Metastatic Gastric Cancer: A Multi-Center Single-Arm Cohort Study.
- Authors
Xin Zhang; Haoran Huo; Yanan Nie; Jiadong Xue; Zengjiang Yuan; Zhenyi Zhang
- Abstract
Purpose: Treatment options are limited after the failure of first-and second-line treatments in patients with HER2+ metastatic gastric cancer (mGC). The present study aimed to explore the efficacy, safety, and prognostic factors of apatinib efficacy as a third-line therapy for patients with human epithelial growth factor receptor 2-positive (HER2+) mGC. Materials and Methods: A total of 59 HER2+ mGC patients who received apatinib as thirdline therapy were retrospectively enrolled in this two-center, single-arm, cohort study; the clinical response, survival data, and adverse events were retrieved. Results: The median progression-free survival (PFS) was 5.2 months (95% confidence interval [CI], 3.9–6.5), and the median overall survival (OS) was 8.2 months (95% CI, 6.6–9.8) Furthermore, forward stepwise multivariate Cox regression analysis showed that a higher Eastern Cooperative Oncology Group performance status score and multiple metastases were independently correlated with decreased PFS and OS (both P<0.05). The main adverse events were leukopenia (45.8%), hypertension (44.1%), thrombocytopenia (39.0%), handfoot syndrome (37.3%), and elevated transaminase (33.9%). Grade 3 adverse events mainly included hypertension (5.1%) and neutropenia (5.1%); grade 4 adverse events did not occur. Conclusions: Apatinib is efficient and well tolerated in patients with HER2+ mGC as a thirdline treatment, suggesting that it may be a candidate of choice for these patients.
- Subjects
APATINIB; STOMACH cancer; METASTASIS; COHORT analysis; PROGNOSIS
- Publication
Journal of Gastric Cancer, 2022, Vol 22, Issue 4, p408
- ISSN
2093-582X
- Publication type
Article
- DOI
10.5230/jgc.2022.22.e33